As we have previously reported, several other investigations have reported the possible increased risk of pancreatitis and pancreatic cancer from the use of incretin mimetic medications.

The British Medical Journal’s (BMJ) investigation into two classes of type-2 diabetes drugs has created cause for concern. The BMJ investigation focused on glucagon-like peptide (GLP-1) agonists and dipeptidylpeptidase-4 inhibitors. The preliminary results suggest that these types of drugs, classified as incretin mimetics, might have an adverse effect on pancreatic function. Even more concerning is the link between the medications and pancreatitis and pancreatic cancer. At one point in the BMJ study, researchers state that a “more coherent and worrying picture emerges” when evidence of the medications’ negative effects on pancreatic functions is considered. The study cites to “emerging and longstanding evidence” for its proposals. An excerpt of the study is available here.

If you or a loved one have suffered from pancreatitis or pancreatic cancer after taking Byetta, Januvia/Janumet or Victoza, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any potential claims.